Recent studies demonstrated that the double rearrangement (double hit) of the MYC and BCL2 genes and the double expression of the MYC and BCL2 proteins were associated with a poor prognosis for patients with nodal DLBCL.7, 8, 9, 10 However, the clinical impact of the double expression of MYC and BCL2 on PG-DLBCL remains unknown. The gene discussed is MYC; the disease is diffuse large B-cell lymphoma.